Tongue Carcinoma

These findings indicate that CCNA2 is a promising diagnostic and prognostic biomarker candidate in OTSCC. Given the small size of the CPTAC validation cohort, further studies in larger, independent OTSCC cohorts are warranted to confirm its clinical utility.

The tumor progressed after two cycles of first-line induction chemotherapy with paclitaxel plus cisplatin. The response to disitamab vedotin, despite prior taxane progression, suggests the potential critical role of HER2-mediated drug delivery and indicates that low antigen density may be sufficient for ADC efficacy. This case indicates the importance of routine HER2 testing with explicit HER2-low categorization in advanced SGCs and offers preliminary evidence that may help expand therapeutic options for this treatment-refractory population.

Eighteen P4-generation PDX mice were randomized into three groups (*n*=6/group): Control: 100 μL/day saline (oral gavage), Cisplatin: 5 mg/Kg/week (intraperitoneal injection), Apatinib: 100 mg/Kg/day (oral gavage). These findings support its potential as a targeted therapy for tongue cancer and highlight the utility of PDX models for preclinical drug evaluation. Further studies with larger cohorts are warranted to validate these results.

Safety evaluations showed good biocompatibility and low systemic toxicity. Overall, this study presents a clinically translatable, integrated strategy for precise surgical margin management in OSCC, spanning the entire perioperative course.

NLR is robust prognostic biomarker in TSCC. The TCIRG1+TAN subset emerges as a superior predictor of adverse outcomes, highlighting its potential as a therapeutic target.

Furthermore, higher Il-4 expressions were noted in OTSCC stroma, evidencing not only a higher response (Th2) in this tumor microenvironment but also suggesting that the lower amounts of Il-4 detected in LLSCCs may be associated with a neoplastic growth inhibition mechanism. These findings corroborate the more aggressive OTSCC behavior in comparison with LLSCCs and emphasize the important role of this cytokine and its application in the fight against cancer.

P=N/A, N=190, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

Clinically, low hsa-circ-0001030 expression correlated with advanced tumor-node-metastasis stage, poor differentiation, and unsatisfying prognosis in TSCC patients. Hsa-circ-0001030 acted as a tumor-suppressive circRNA that might depress PKM2-dependent metabolic reprogramming and cisplatin resistance in TSCC, highlighting its potential as a prognostic biomarker and therapeutic target for overcoming chemoresistance.

Effect size estimates were relatively large for both the group effect (partial η2=0.20) and the time x group interaction (partial η2=0.24), suggesting that the study may have been underpowered to detect this difference statistically. In conclusion, the present exploratory study suggests that suramin exerts a dual antitumor effect on tongue squamous cell carcinoma by suppressing proliferative transcriptional programs, and modulating extracellular and stress response pathways, providing a basis for future studies to further elucidate its therapeutic relevance.

P=N/A, N=600, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Moreover, these tumors also showed lower expression of tumor proliferative and neuron markers. Together these findings established cancer cell secreted PTHLH as a critical mediator of immunosuppression and neuron infiltrations in HNSCC, particularly in tongue tumor.